EGFR and non-small cell lung carcinoma: In addition, prior studies have shown that anlotinib plus other EGFR‐TKIs (gefitinib, afatinib) overcome acquired resistance to EGFR‐TKI in patients with advanced EGFR‐mutant NSCLC [25, 26].